Nice to Michu
14 Dec 2017
some good news a decent per cent of any future revenues without any more cash commitment thru remaining testing etc.. 5m Cash in the bank is very useful too.. I added some this morning and had hoped for 20p today .. unlikely now i'm thinking.. so I'll probably trade out of some of this today but will keep a core holding here and think that the s/p market cap. feels still extremely low here.. so much room for future s/p growth .. assuming they continue to progress their prospective treatments incrementally towards market, of course .. DYOR of cours
Bitethebull
27 Oct 2017
Re: Rns's No problem, but it does seem that things have turned poitive again. Potential is huge if all goes well.
charlie51
27 Oct 2017
Re: Rns's My error - I saw 27th and thought that it was today...not last month. Been in this for ages so no a downhill ride, and I don't check the BB very often - not until this morning. Glad I did as I'm quite encouraged by the news, albeit it being a month old.
Bitethebull
27 Oct 2017
Rns's What RNS'S ???
charlie51
27 Oct 2017
RNSs The most encouraging news on SNG for sometime. Good to see. Hopefully, the SP will now move into a sustained recovery.
mr1christian
08 Sep 2017
Pharmaxis on LOXL Synairgen partnering Pharmaxis 50/50 as the drug goes into phase 1 trials[link] still hugely undervalued ,....
Disorder
27 Apr 2017
Shame. Synairgen plc('Synairgen' or the 'Company')AZD9412 Update · Cold infections did not affect trial patients' asthma in the INEXAS study as much as predicted, meaning that the drug's effects on severe exacerbations could not be determined· Treatment with AZD9412 switched on antiviral responses in the lungs, improved morning peak flow (a measure of lung function), and was well tolerated· The study however, did not meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen· Synairgen will conduct further analysis of the data and determine future development routes Southampton, UK - 27th April 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today provides an update on AZD9412 (inhaled interferon beta). In October 2016 Synairgen provided the market with an update on the INEXAS trial of AZD9412, a novel, inhaled interferon beta that supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections (primarily common cold viruses). The trial was stopped early due to a low severe exacerbation event rate which compromised an assessment of this endpoint (number of severe exacerbations).Treatment with inhaled interferon beta did however switch on the lungs' antiviral defences (as measured by blood levels of the antiviral biomarker CXCL10), have a beneficial effect on lung function (Morning Peak Expiratory Flow: difference of 19.7 litres per minute average over the first 7 days of treatment (p=0.01)), and was well tolerated. Effects on biomarkers, lung function and the good tolerability profile were consistent with the Company's own Phase II trial (SG005). The study did not however meet AstraZeneca's predefined criteria for progression, and they have elected to return the rights to AZD9412 to Synairgen.Further analysis of samples from the trial is being completed by AstraZeneca. Data from this sample analysis and the clinical trial data will be licensed to Synairgen. Synairgen will complete the data analysis and will use this as a basis to determine the future direction of the programme.Professor Stephen Holgate CBE, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton, said: "We believe that the biomarker, lung function and safety data from this and our previous study continue to support the potential of inhaled interferon beta as a treatment for vulnerable patients whose disease control is badly affected when they get a cold. We are particularly interested in the potential for COPD, where exacerbations are associated with disease progression and an increased risk of dying. Since we licensed this programme to AstraZeneca, the weight of data linking viruses to COPD exacerbations has increased, and the link of colds to secondary bacterial infections has become widely accepted."Richard Marsden, CEO of Synairgen, said: "We remain positive about the potential of inhaled interferon beta, particularly for patients with COPD who suffer due to respiratory viruses. Once we have completed the data analysis, we will provide an update on the programme and our plans for future development."
high blood pressure1
10 Mar 2017
Re: 
Yes very encouraging. Also waiting for the akzo decision or not?5th and for the tippage. Up a great deal again!
high blood pressure1
10 Mar 2017
Re: Yes very encouraging. Also waiting for the akzo decision or not?Thanks for the tippage. Up a great deal again!
Disorder
10 Mar 2017
Well, thats good news isnt it.?
high blood pressure1
17 Feb 2017
Re: Disorder-last post So basically anyone that buys a share based on one or more people's views on an open and non transparent discussion board deserves whatever losses they get!I have lost thousands speculating on the back of very reputable "tipsters" in the press - but even after their losses hey are seen as "analysts" not rampers or the like.I think disorder stated facts at 18p. That despite the recent halt to product testing, a director has purchase a large amount of shares. That's all it is - facts.I've seen a whole lot worse than this trust me.So be bitter or whatever else you want to be but I don't think the abuse is justif
The Duckie of Cornwall
17 Feb 2017
Re: Disorder-last post You can't claim all the credit for yourself; that would be too greedy.Off to feed the pheasants.
Disorder
17 Feb 2017
Re: Disorder-last post God forbid i sinle handedly get the blame now for this mornings rise again.Good job things never go up in a dead straight line, if they did the conspiracy theorists would have to find another reason to give their arguments a form of credibility.PS: i did not buy the top sliced shares i sold back. Happy with my holding here.
BLUE-BOTTLE
17 Feb 2017
Re: Disorder-last post In my experience those involved in BB arguments over ramping/de-ramping are usually in it together. Boom!!
The Duckie of Cornwall
17 Feb 2017
Re: Disorder-last post I'm not taking sides but do chill; one of the ways to shorten one's life is to be bitter and angry; blood pressure goes up and puts strain on the heart..We are all big boys and girls and can look after ourselves in this particular playground.Live long and prosper (No I'm not a Trekkie but it's sort of appropriate)
